Cancer Research UK, its innovation unit, Cancer Research Horizons, and Guardant Health announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment. The agreement will enable the parties to discuss opportunities for collaboration to support the charity’s research and clinical development activities, focusing primarily on its clinical trials run by its Centre for Drug Development. This includes the DETERMINE trial – the first UK national precision medicine trial in rare cancers, and other Cancer Research UK and Cancer Research Horizons research collaborations. Additional potential collaboration activities may include sharing data and samples from the Cancer Research UK-funded research network to further develop and validate Guardant’s technologies, as well as explore other projects to accelerate the discovery and development of cancer drugs and diagnostics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH:
- Guardant Health to appeal intellectual property federal district court verdict
- Guardant Health upgraded to Outperform from Market Perform at Raymond James
- Guardant launches Shield blood-based screening test for CRC in South Korea
- Guardant Health price target lowered to $64 from $74 at Craig-Hallum
- Guardant Health raises FY23 revenue view to $553M-$556M, consensus $549.06M